All In MedTech

FDA Clearance Tracker · P010031-S569

Amplia MRI and Amplia MRI Quad CRT-D SureScan , Compia MRI and Compia MRI Quad CRT-D SureScan, Claria MRI and Claria MRI

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 25, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 25, 2017

Approved

Time to decision

174 days

Received Nov 2, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P010031-S569
Device name
Amplia MRI and Amplia MRI Quad CRT-D SureScan , Compia MRI and Compia MRI Quad CRT-D SureScan, Claria MRI and Claria MRI
Applicant location
Mounds View, MN
Received
Nov 2, 2016
Decided
Apr 25, 2017
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P010031

Device type

Device class
Class III

Every decision under product code NIK

FDA's approval statement

As written in FDA's record.

Approval of 1.5 and 3T MR Conditional Labeling for SelectSecure MRI SureScan Lead Model 3830.

Source documents

Other decisions for Medtronic Cardiac Rhythm Disease Management

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.